Phio Pharmaceuticals Corp is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform. The Company's pipeline consists of RXI-762 and RXI-804 which are in clinical stage. Phio Pharmaceuticals Corp, formerly known as RXi Pharmaceuticals Corporation, is based in Marlborough, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-10.83M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.34 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -134.66% |
| Return on Assets (Trailing 12 Months) | -105.86% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.20 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.93 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 4.59M |
| Free Float | 4.56M |
| Market Capitalization | $3.24M |
| Average Volume (Last 20 Days) | 0.46M |
| Beta (Past 60 Months) | 1.44 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.77% |
| Percentage Held By Institutions (Latest 13F Reports) | 57.31% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |